SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Divi’s Laboratories tumbles on reporting 42% fall in Q1 net profit

24 Jul 2017 Evaluate

Divi’s Laboratories is currently trading at Rs. 689.40, down by 31.45 points or 4.36% from its previous closing of Rs. 720.85 on the BSE.

The scrip opened at Rs. 699.75 and has touched a high and low of Rs. 699.75 and Rs. 680.35 respectively. So far 2,06,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1380.00 on 16-Sep-2016 and a 52 week low of Rs. 533.10 on 29-May-2017.

Last one week high and low of the scrip stood at Rs. 768.00 and Rs. 680.35 respectively. The current market cap of the company is Rs. 18,301.00 crore.

The promoters holding in the company stood at 52.07%, while Institutions and Non-Institutions held 31.42% and 16.51% respectively.

The company has reported 41.51% fall in its net profit at Rs 176.54 crore for first quarter ended June 30, 2017 as compared to Rs 301.81 crore for the same quarter in the previous year. Total revenue from operations of the company decreased by 17.67% at Rs 850.88 crore for Q1FY18 as compared Rs 1033.50 crore for the corresponding quarter previous year.

Divi’s Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.


Divis Lab Share Price

6378.75 90.30 (1.44%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×